Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $2.1 million.

  • Janux Therapeutics' Depreciation & Amortization (CF) fell 1.76% to $501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 0.29%. This contributed to the annual value of $2.1 million for FY2024, which is 5.37% up from last year.
  • As of FY2024, Janux Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million, which was up 5.37% from $2.0 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Depreciation & Amortization (CF) ranged from a high of $2.1 million in FY2024 and a low of $13,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $1.6 million, with a median of $2.0 million in 2023.
  • Data for Janux Therapeutics' Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 769.23% (in 2021) over the last 5 years.
  • Janux Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $13,000 in 2020, then spiked by 769.23% to $113,000 in 2021, then soared by 644.25% to $841,000 in 2022, then soared by 132.46% to $2.0 million in 2023, then climbed by 5.37% to $2.1 million in 2024.